MDxHealth SA Stock Euronext Bruxelles
Stocks
MDXH
BE0974461940
Biotechnology & Medical Research
| Market Cap | 20.48M 23.68M 19.13M 17.55M 33M 2.25B 33.53M 224M 88.08M 1.13B 88.92M 86.97M 3.73B | P/E 2026 * |
-0.71x | P/E 2027 * | -1.03x |
|---|---|---|---|---|---|
| Enterprise Value | 142M 165M 133M 122M 230M 15.67B 233M 1.56B 613M 7.86B 618M 605M 25.97B | EV / Sales 2026 * |
1.49x | EV / Sales 2027 * | 1.49x |
| Free-Float |
88.87% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MDxHealth SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 18/02/2019 | |
Ron Kalfus
DFI | Director of Finance/CFO | 52 | 22/07/2019 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hilde Windels
BRD | Director/Board Member | 61 | 01/11/2017 |
Koen Hoffman
CHM | Chairman | 58 | 01/01/2018 |
| Director/Board Member | 64 | 18/02/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.58% | - | - | 23.68M | |
| +1.07% | +3.21% | +6.84% | +16.08% | 49.47B | |
| -0.01% | +13.26% | +495.50% | +593.19% | 43.97B | |
| +2.51% | +14.05% | +23.51% | +80.81% | 39.6B | |
| +1.14% | +3.31% | +33.87% | +8.70% | 39.29B | |
| +0.85% | +7.66% | +21.22% | +48.78% | 32.43B | |
| -0.42% | +4.52% | - | - | 16.84B | |
| +0.90% | +4.07% | +32.66% | +122.92% | 16.49B | |
| +0.34% | +3.40% | +5.70% | +18.79% | 14.01B | |
| +0.83% | +16.52% | +80.63% | +23.62% | 12.77B | |
| Average | +0.72% | +6.18% | +87.49% | +114.11% | 29.43B | |
| Weighted average by Cap. | +0.93% | +5.95% | +107.75% | +139.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 95.89M 111M 89.55M 82.15M 155M 10.55B 157M 1.05B 412M 5.29B 416M 407M 17.48B | 108M 125M 101M 92.43M 174M 11.87B 177M 1.18B 464M 5.95B 468M 458M 19.67B |
| Net income | -28M -32.36M -26.14M -23.98M -45.11M -3.08B -45.82M -307M -120M -1.54B -122M -119M -5.1B | -17.95M -20.75M -16.76M -15.38M -28.92M -1.97B -29.38M -197M -77.19M -990M -77.92M -76.22M -3.27B |
| Net Debt | 122M 141M 114M 104M 197M 13.42B 200M 1.34B 525M 6.73B 530M 518M 22.24B | 140M 162M 131M 120M 226M 15.41B 229M 1.53B 602M 7.73B 608M 595M 25.54B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
